13th International
symposium on MPS and
related diseases
13th International
symposium on MPS and
related diseases
13th International
symposium on MPS and
related diseases
13th International
symposium on MPS and
related diseases
MOGAM has exceptional history of experience specializing in developing protein-based therapeutics, such as PEGylated G-CSF, coagulation factors, and monoclonal antibodies. Moving towards the next generation of therapeutics, we are now focusing on mRNA-based therapeutics. Based on our existing competencies, we have been researching mRNA components and nanoparticles (NPs) and increasing our competitiveness through open innovation.
An antibody library is an essential and important platform in the field of discovery of antibody therapeutics. MOGAM has generated two formats of antibody libraries with Fab and heavy chain variable domains (VH). The human-like synthetic Fab library constructed by combining the high throughput sequencing (HT-sequencing) information about the human variable gene repertoire, and a novel approach to design synthetic codons. We confirmed that the design of CDRs was precisely embodied in the library with an expected quality by HT sequencing. The VH domain library was constructed using rationally controlled CDRs to overcome the lack of binding sites and further engineered to have high levels of thermodynamic stability, soluble expression, and reversible folding.
Antibodies can be effectively generated through a B cell library using human and mouse immune responses and a synthetic library of various antibody formats.
- Using structure analysis software to perform structure modeling and simulation docking, etc.
- Library design to improve protein efficacy based on the analyzed data
MOGAM developed hyper-stable VH domain antibody similar to the igG level using own protein engineering & screening system
Easy to multimerization for binding various targets